Literature DB >> 30636552

Increased Preeclampsia Risk and Reduced Aortic Compliance With In Vitro Fertilization Cycles in the Absence of a Corpus Luteum.

Frauke von Versen-Höynck1,2, Amelia M Schaub3, Yueh-Yun Chi4, Kuei-Hsun Chiu4, Jing Liu4, Melissa Lingis5, R Stan Williams3, Alice Rhoton-Vlasak3, Wilmer W Nichols6, Raquel R Fleischmann1, Wendy Zhang1, Virginia D Winn7, Mark S Segal5, Kirk P Conrad3,8, Valerie L Baker1.   

Abstract

In vitro fertilization involving frozen embryo transfer and donor oocytes increases preeclampsia risk. These in vitro fertilization protocols typically yield pregnancies without a corpus luteum (CL), which secretes vasoactive hormones. We investigated whether in vitro fertilization pregnancies without a CL disrupt maternal circulatory adaptations and increase preeclampsia risk. Women with 0 (n=26), 1 (n=23), or >1 (n=22) CL were serially evaluated before, during, and after pregnancy. Because increasing arterial compliance is a major physiological adaptation in pregnancy, we assessed carotid-femoral pulse wave velocity and transit time. In a parallel prospective cohort study, obstetric outcomes for singleton livebirths achieved with autologous oocytes were compared between groups by CL number (n=683). The expected decline in carotid-femoral pulse wave velocity and rise in carotid-femoral transit time during the first trimester were attenuated in the 0-CL compared with combined single/multiple-CL cohorts, which were similar (group-time interaction: P=0.06 and 0.03, respectively). The blunted changes of carotid-femoral pulse wave velocity and carotid-femoral transit time from prepregnancy in the 0-CL cohort were most striking at 10 to 12 weeks of gestation ( P=0.01 and 0.006, respectively, versus 1 and >1 CL). Zero CL was predictive of preeclampsia (adjusted odds ratio, 2.73; 95% CI, 1.14-6.49) and preeclampsia with severe features (6.45; 95% CI, 1.94-25.09) compared with 1 CL. Programmed frozen embryo transfer cycles (0 CL) were associated with higher rates of preeclampsia (12.8% versus 3.9%; P=0.02) and preeclampsia with severe features (9.6% versus 0.8%; P=0.002) compared with modified natural frozen embryo transfer cycles (1 CL). In common in vitro fertilization protocols, absence of the CL perturbed the maternal circulation in early pregnancy and increased the incidence of preeclampsia.

Entities:  

Keywords:  hormones; humans; pregnancy; pulse wave analysis; relaxin

Mesh:

Year:  2019        PMID: 30636552      PMCID: PMC6434532          DOI: 10.1161/HYPERTENSIONAHA.118.12043

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  52 in total

1.  Maternal and neonatal outcomes associated with trophectoderm biopsy.

Authors:  Wendy Y Zhang; Frauke von Versen-Höynck; Kristopher I Kapphahn; Raquel R Fleischmann; Qianying Zhao; Valerie L Baker
Journal:  Fertil Steril       Date:  2019-05-15       Impact factor: 7.329

Review 2.  Evidence for Corpus Luteal and Endometrial Origins of Adverse Pregnancy Outcomes in Women Conceiving with or Without Assisted Reproduction.

Authors:  Kirk P Conrad
Journal:  Obstet Gynecol Clin North Am       Date:  2020-03       Impact factor: 2.844

3.  Maternal endothelial function, circulating endothelial cells, and endothelial progenitor cells in pregnancies conceived with or without in vitro fertilization.

Authors:  Kirk P Conrad; Melissa Lingis; Larysa Sautina; Shiyu Li; Yueh-Yun Chi; Yingjie Qiu; Mingyue Li; R Stan Williams; Alice Rhoton-Vlasak; Mark S Segal
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-04-29       Impact factor: 3.619

4.  Assisted reproductive technologies induce temporally specific placental defects and the preeclampsia risk marker sFLT1 in mouse.

Authors:  Lisa A Vrooman; Eric A Rhon-Calderon; Olivia Y Chao; Duy K Nguyen; Laren Narapareddy; Asha K Dahiya; Mary E Putt; Richard M Schultz; Marisa S Bartolomei
Journal:  Development       Date:  2020-05-29       Impact factor: 6.868

5.  Maternal Cardiovascular Dysregulation During Early Pregnancy After In Vitro Fertilization Cycles in the Absence of a Corpus Luteum.

Authors:  Kirk P Conrad; John W Petersen; Yueh-Yun Chi; Xiaoman Zhai; Minjie Li; Kuei-Hsun Chiu; Jing Liu; Melissa D Lingis; R Stan Williams; Alice Rhoton-Vlasak; Joseph J Larocca; Wilmer W Nichols; Mark S Segal
Journal:  Hypertension       Date:  2019-07-29       Impact factor: 10.190

6.  Potential influence of the corpus luteum on circulating reproductive and volume regulatory hormones, angiogenic and immunoregulatory factors in pregnant women.

Authors:  Kirk P Conrad; Georgia M Graham; Yueh-Yun Chi; Xiaoman Zhai; Minjie Li; R Stan Williams; Alice Rhoton-Vlasak; Mark S Segal; Charles E Wood; Maureen Keller-Wood
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-08-13       Impact factor: 4.310

7.  Preeclampsia: Linking Placental Ischemia with Maternal Endothelial and Vascular Dysfunction.

Authors:  Bhavisha A Bakrania; Frank T Spradley; Heather A Drummond; Babbette LaMarca; Michael J Ryan; Joey P Granger
Journal:  Compr Physiol       Date:  2020-12-09       Impact factor: 9.090

8.  In vitro fertilization and risk for hypertensive disorders of pregnancy: associations with treatment parameters.

Authors:  Barbara Luke; Morton B Brown; Michael L Eisenberg; Caitriona Callan; Beverley J Botting; Allan Pacey; Alastair G Sutcliffe; Valerie L Baker
Journal:  Am J Obstet Gynecol       Date:  2019-10-17       Impact factor: 8.661

9.  Maternal Vascular Health in Pregnancy and Postpartum After Assisted Reproduction.

Authors:  Frauke von Versen-Höynck; Sebastian Häckl; Elif Seda Selamet Tierney; Kirk P Conrad; Valerie L Baker; Virginia D Winn
Journal:  Hypertension       Date:  2019-12-16       Impact factor: 10.190

10.  Determinants of Maternal Renin-Angiotensin-Aldosterone-System Activation in Early Pregnancy: Insights From 2 Cohorts.

Authors:  Rosalieke E Wiegel; A H Jan Danser; Régine P M Steegers-Theunissen; Joop S E Laven; Sten P Willemsen; Valerie L Baker; Eric A P Steegers; Frauke von Versen-Höynck
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.